{
  "id": 16822333,
  "title": "Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial",
  "url": "https://urgent.news/2026/10/28/novel-alpha-radiopharmaceutical-therapy-shows-promise-in-early-phase",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T00:00:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-alpha-radiopharmaceutical-therapy-early-phase.html"
  },
  "original_language": "en",
  "account": "A Phase I trial of 22 patients with metastatic prostate cancer showed that the alpha-emitting radiopharmaceutical therapy ²¹²Pb-ADVC001 was well tolerated, with no serious adverse events reported. The therapy, targeted to prostate-specific membrane antigen (PSMA), resulted in PSA levels declining by at least 50% in 80% of patients and a median radiographic progression-free survival of 11.2 months. With an overall response rate of 100%, the study authors believe further clinical development of ²¹²Pb-ADVC001 could address unmet needs in treating metastatic prostate cancer, particularly for patients resistant to beta-emitting radiopharmaceuticals.",
  "summary": "A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}